Joyonna Gamble-George, PhD
Joyonna Gamble-George is a former Early Career Policy Ambassador (ECPA) for SfN. She is also a senior scientific officer for SciX, LLC, a biotech Internet of Things software applications and device development company. She earned her BS in biochemistry and biology from Xavier University of Louisiana, her MHA in health administration from the University of South Florida College of Public Health, and her PhD in neuroscience from Vanderbilt University. She recently completed postdoctoral training at the University of Florida, where her research focused on the effects of methamphetamine on bidirectional neuron-microglia communication in the human brain and animal models of HIV-1 infection. Her previous research efforts concerned potential drug therapies for Alzheimer's disease, the molecular and synaptic consequences of drug abuse and addiction, and endocannabinoid signaling in affective disorder pathology using mouse models.
Kristin Anderson is a PhD candidate at Lehigh University. Anderson studies how genes encoding for protein modulators of the cholinergic system affect nicotinic acetylcholine receptors and behaviors such as fear, anxiety, and learning in mouse-to-human correlative studies. As a science advocate, Anderson engages the public as well as congressional leaders to promote robust and sustained science funding. Through her refined communication techniques, she connects the dots between science funding and how the resulting research benefits society. She has attended SfN’s Hill Day and the Rally for Medical Research on Capitol Hill, attends local town hall meetings with Congress, regularly writes advocacy related news articles, and has brought science and advocacy to the public through science fairs and music festivals.
Megan Anderson Brooks, PhD
As a vice president at CRD Associates, Megan Anderson Brooks focuses on science and regulatory policy related to basic and clinical scientific research, personalized medicine, federal oversight of diagnostics and biotech devices, and patient-specific issues related to access and patient-centered treatment development. On behalf of clients, she assists in the development and implementation of policy strategies, coordinates congressional briefings and public policy symposiums, organizes client advocacy days on Capitol Hill, and engages in direct lobbying. She was a neuroscientist for more than 10 years, during which she conducted research on brain health and the neural mechanisms of learning and memory. She previously worked for the Society for Neuroscience on issues related to research replicability and to develop grassroots advocacy activities. She holds a PhD in neuroscience from Rutgers University and was awarded a fellowship from the Eagleton Institute of Politics.
Moses V. Chao, PhD
Moses V. Chao is a professor in the departments of cell biology, physiology, and neuroscience and of psychiatry at the NYU School of Medicine, where he is also director of the NYU Medical Center neuroscience graduate program. His laboratory defined the genes encoding the NGF receptor, and his research interests lie in defining mechanisms used by trophic factors to change synaptic plasticity. Chao served as president of the Society for Neuroscience from 2011–12 and as senior editor of JNeurosci for 11 years. He additionally has served on scientific advisory boards for the Simons Foundation, Target ALS, the Pershing Square Sohn Cancer Research Alliance, the European Brain Research Institute, the Brain Prize Advisory Committee, the Danish Research Institute of Translational Neuroscience, the Christopher and Dana Reeve Foundation, the New York Stem Cell Foundation, and St. Jude’s Children’s Research Hospital. He is a AAAS Fellow as well as the recipient of a Zenith Award from the Alzheimer’s Association, an NIH Jacob Javits Neuroscience Investigator Award, a Guggenheim Fellowship, and SfN’s Julius Axelrod Prize. He received his BA degree from Pomona College and his PhD in biochemistry from UCLA.